1. Home
  2. |Insights
  3. |Double Whammy: NIST Unveils Draft Enhanced Security Requirements and Revisions to NIST SP 800-171

Double Whammy: NIST Unveils Draft Enhanced Security Requirements and Revisions to NIST SP 800-171

Client Alert | 1 min read | 06.21.19

The National Institute of Standards and Technology (NIST) has released drafts of NIST SP 800-171 Revision 2 and a companion standard NIST SP 800-171B, designed to protect Controlled Unclassified Information (CUI) from advanced persistent threats (APTs). 800-171B details 33 “enhanced” controls, reflecting core principles of penetration resistance, damage-limiting operations, and resiliency. Specific controls include those related to segregation, hunt teams, AI-enabled tools, IoT security, and supply chain – some of which arguably do not have firm industry definitions.

Unlike the non-substantive updates to Revision 2, 800-171B will apply only to contractors handling CUI that the government determines is part of a “critical program” or is a “high value asset.” A cost estimate from the Department of Defense – expected to quickly implement 800-171B – anticipates that less than one percent of its contractors will be impacted but that (allowable) costs could exceed $1 million.

Comments for all three documents are due July 19, 2019. 

Contacts

Insights

Client Alert | 4 min read | 04.10.25

Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”

In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia....

View All Insights